Singulex is an immunodiagnostics company at the forefront of Single Molecule Counting technology, a novel immunoassay technology recognized for unprecedented ultra-sensitivity in the precision measurement of biomarkers. Singulex is the developer of the Singulex Clarity system, a fully-automated, in vitro diagnostics platform powered by Single Molecule Counting technology. With up to 1000 times more sensitivity than existing technologies, Single Molecule Counting reveals the presence or absence of disease more clearly and definitively than was possible before. In 2017, Singulex filed a 510(k) pre-market notification submission with the U.S. Food and Drug Administration. The Singulex Clarity system and Singulex Clarity assay have the CE mark and are commercially available in Europe. Additional assays to detect and rule out infectious and inflammatory diseases are in development. Singulex is also developing a point-of-care platform and exploring applications beyond the clinical setting.
For more information, please visit singulex.com or singulexclarity.eu
For more information, please visit singulex.com or singulexclarity.eu
Location: United States, California, Alameda
Employees: 201-500
Total raised: $84.5M
Founded date: 1997
Investors 3
Funding Rounds 3
| Date | Series | Amount | Investors |
| 26.09.2013 | - | $55M | - |
| 14.01.2009 | - | $19M | - |
| 20.09.2006 | - | $10.5M | - |
Mentions in press and media 5
| Date | Title | Description |
| 26.09.2013 | Singulex Closes $55M Financing | Singulex, Inc., a Alameda, CA-based provider of Single Molecule Counting (SMC™) technology for scientific discovery and clinical testing services, closed a $55m financing. It includes a debt facility for up to $40m from Oxford Finance and S... |
| 14.01.2009 | Singulex lands $19M for diagnostic systems | Singulex, an Alameda, Calif.-based biotech firm, just raised $19 million in fifth-round funding to commercialize technology that uses protein biomarkers to diagnose cardiovascular and other disorders. Already in clinical trials, its system ... |
| 08.06.2007 | Biomarker diagnostics company Singulex raises $19M | See our story here at VentureBeat LifeSciences. VentureBeat VentureBeat's mission is to be a digital townsquare for technical decision makers to gain knowledge about transformative technology and transact. Our site delivers essential inform... |
| 07.06.2007 | Biomarker-diagnostics developer Singulex validates $19M | Hayward, Calif.-based Singulex, a developer of sensitive molecular-detection systems, raised $19 million in a fourth funding round. The company’s release is here. The company is developing an analysis system, called Erenna, plus related “as... |
| 20.09.2006 | Molecular detection Co., Singulex, raises $10.5M | Singulex, a Hayward company developing “bio-markers” to detect the presence in the body of certain proteins that might suggest disease, said it has raised $10.5 million in series C and debt financing deals. It also said it has added Mickey ... |